NCT00256191CompletedPhase 1
A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies
Cortice Biosciences, Inc.2 sites in 1 country45 target enrollmentStarted: November 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Cortice Biosciences, Inc.
- Enrollment
- 45
- Locations
- 2
- Primary Endpoint
- To determine the maximum tolerated dose of TPI 287 administered every 21 days
Study Overview
Brief Summary
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material. The synthesis involves modification to the taxane side chain to overcome multidrug resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose escalation, sequential group, Phase 1 study evaluating the intravenous administration of TPI 287 on an every 21 day cycle.
Detailed Description
The primary objective of this study is to determine the maximum tolerated dose of TPI 287 administered every 21 days for Phase II clinical trials.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must be/have:
- •Histological evidence of malignancy
- •Advanced solid tumors that have recurred or progressed following standard therapy
- •Failed one prior therapy or have no standard therapy available
- •Ambulatory with ECOG of 0-1 and estimated life expectancy of > 3 months
- •If female, negative pregnancy test
- •If of childbearing years, agree to use birth control
- •If patient with prior radiation therapy for brain metastases, on steroids, must have been stable for 1 month
Exclusion Criteria
- •Patients will be excluded if they are or have had:
- •Prior radiation within 4 weeks
- •Active medical condition or organ disease which may compromise safety or interfere with the study
- •Clinically significant cardiac co-morbidities or pulmonary impairment
- •Concomitant therapy needs
- •Treated with any investigational drugs within 30 days
- •Tumors involve major artery or vein
- •Prior or concurrent central nervous system (CNS) disease
- •Less than 4 weeks since major surgery
- •Known to be positive for HIV, hepatitis B or C
- •Concurrent use of aspirin
- •Use of thrombolytic agents
- •Uncontrolled hypertension
- •Grade II-IV peripheral vascular disease
- •Pregnant or lactating
- •Prior allergic history to compounds of similar chemical composition
- •Inpatients
- •Grade II-IV peripheral neuropathy
Outcomes
Primary Outcomes
To determine the maximum tolerated dose of TPI 287 administered every 21 days
Secondary Outcomes
- To determine the safety of TPI 287
- To determine the antitumor activity of TPI 287
- To determine the pharmacokinetic profile of TPI 287
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Study of TPI 287 in Patients With Advanced MalignanciesNeoplasmsNon-Hodgkin LymphomaHodgkin DiseaseNCT00113724Cortice Biosciences, Inc.48
Terminated
Phase 1
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorHead and Neck Squamous Cell Carcinoma HNSCCHPV-associated CancersNeoadjuvant MelanomaNeoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)NCT04799054Ascendis Pharma Oncology Division A/S188
Withdrawn
Phase 1
Open-Label Study of TPI 287 for Patients With Metastatic MelanomaMetastatic MelanomaNCT01340729M.D. Anderson Cancer Center
Completed
Phase 1
A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With GemcitabineSolid Tumors and Non-Hodgkin's LymphomaNCT02018874Gustave Roussy, Cancer Campus, Grand Paris52
Terminated
Phase 1
A Phase I Study of TPI 287 - Temozolomide Combination in MelanomaMelanomaNCT01067066M.D. Anderson Cancer Center21